Compounds > 3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol
Page last updated: 2024-11-04

3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol and Opioid-Related Disorders

3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol has been researched along with Opioid-Related Disorders in 1 studies

3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol: RN given refers to (+/-)-isomer; RN, RRs & structure given in first source

Opioid-Related Disorders: Disorders related to or resulting from abuse or misuse of OPIOIDS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Caine, SB1
Koob, GF1
Parsons, LH1
Everitt, BJ1
Schwartz, JC1
Sokoloff, P1

Other Studies

1 other study available for 3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol and Opioid-Related Disorders

ArticleYear
D3 receptor test in vitro predicts decreased cocaine self-administration in rats.
    Neuroreport, 1997, Jul-07, Volume: 8, Issue:9-10

    Topics: Animals; Benzopyrans; Benzothiazoles; Cocaine; Dopamine Agonists; Dopamine Antagonists; In Vitro Tec

1997